What Your C-Peptide Level Reveals About Your Type 1 Diabetes Risk

When your pancreas makes insulin, it releases two things at the same time: the insulin your body needs, and a byproduct called C-peptide. Measuring C-peptide in your blood is a way to estimate how much insulin your own pancreas is still producing—something called 'residual beta cell function.'

In Type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. But this destruction doesn't always happen all at once. Some people retain small amounts of their own insulin production for years or even decades after diagnosis. The amount of C-peptide you have is a marker of how much of this function you've preserved.

Researchers from Scotland tracked 5,630 people with Type 1 diabetes, most with over 20 years of disease history, for an average of nearly 11 years. They measured C-peptide levels once at the start and, in a smaller subgroup of 407 people, again during follow-up.

The study used electronic health records to count serious complications—including hospitalizations for dangerous blood sugar emergencies, eye disease, heart attacks, and deaths. This allowed them to see which people actually experienced these events over the years ahead.

People with higher baseline C-peptide levels had notably fewer cases of diabetic ketoacidosis (DKA), a life-threatening condition where blood becomes too acidic. This association was very strong and held true across the study population.

Higher C-peptide was also protective against severe hypoglycemia requiring hospitalization—an event that occurred over 500 times in the cohort. The relationship remained clear even when researchers adjusted their analysis for A1C levels, the standard marker of long-term blood sugar control.

Retinopathy, or damage to the blood vessels of the eye, was also less common in people with higher C-peptide. Again, this protective effect was not fully explained by A1C levels alone.

Interestingly, C-peptide levels were not associated with cardiovascular disease (heart attack and stroke) or death in this cohort. This suggests that whatever protection C-peptide offers is specific to certain complications—not a blanket defense against all diabetes-related health risks.

The study documents *that* preserved insulin production is linked to better outcomes, but it does not explain *why*. Whether C-peptide itself provides some protective effect, or whether people who retain more beta cell function have fundamentally different disease biology, remains an open question.

This work reinforces why scientists continue to pursue therapies aimed at slowing or halting the loss of beta cell function in new-onset Type 1 diabetes. If preserving even modest amounts of your own insulin production correlates with major reductions in serious complications, then interventions that extend this window of residual function could have real clinical value.

For people already living with Type 1 diabetes, these findings underscore the importance of good metabolic management, while acknowledging that blood sugar control alone doesn't capture all the benefits of preserved insulin production.

Source: Diabetes care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.